TCM
MDGL icon

Towercrest Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Towercrest Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,500
Closed -$367K – 83
2020
Q1 		$367K Buy
+5,500
New +$458K 0.11% 56

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Towercrest Capital Management's MDGL Position: Q2 2020 in Review

Towercrest Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2020, closing a stake of 5,500 shares — an estimated $367K sold.

Towercrest Capital Management first reported a position in MDGL in Q1 2020 and held it in 1 quarter. The position peaked at $367K in Q1 2020. 125 funds tracked by Wall St. Rank hold MDGL as of Q2 2020.

  • Towercrest Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Towercrest Capital Management sold 5,500 Madrigal Pharmaceuticals shares in Q2 2020, an estimated $367K.
  • Towercrest Capital Management first reported a position in Madrigal Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Towercrest Capital Management's Madrigal Pharmaceuticals position peaked at $367K in Q1 2020.
  • 125 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2020.

Based on Towercrest Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.